designed to maximize efficacy, improve safety and enhance compliance.

Proven efficacy with IV Iloprost
Most potent PAH treatment on a molar basis
Compatible with the smallest, most reliable pump available
Fewer refills
Less frequent refills/maintenance than any other delivery system

PulmoProst® will Redefine the Management of Pulmonary Arterial Hypertension (PAH)

Led by a dynamic and proven team of pharmaceutical and biotechnology industry executives along with leading scientists and physicians, Infusyn is redefining the management of PAH – a $6 billion market.

Our potential lead candidate, PulmoProst™ promises to optimize treatment and improve outcomes in PAH. Infusyn has completed a Special Protocol Assessment (SPA) with the US FDA.

Represents an unmet need with a considerable market opportunity